Literature DB >> 28664413

Molecular profiling of sarcomas: new vistas for precision medicine.

Tariq Al-Zaid1, Wei-Lien Wang2,3,4, Neeta Somaiah5, Alexander J Lazar6,7,8.   

Abstract

Sarcoma is a large and heterogeneous group of malignant mesenchymal neoplasms with significant histological overlap. Accurate diagnosis can be challenging yet important for selecting the appropriate treatment approach and prognosis. The currently torrid pace of new genomic discoveries aids our classification and diagnosis of sarcomas, understanding of pathogenesis, development of new medications, and identification of alterations that predict prognosis and response to therapy. Unfortunately, demonstrating effective targets for precision oncology has been elusive in most sarcoma types. The list of potential targets greatly outnumbers the list of available inhibitors at the present time. This review will discuss the role of molecular profiling in sarcomas in general with emphasis on selected entities with particular clinical relevance.

Entities:  

Keywords:  Immune checkpoint inhibitors; Immunotherapy; Molecular diagnostics; Next generation sequencing (NGS); Sarcoma; Targeted therapy

Mesh:

Substances:

Year:  2017        PMID: 28664413     DOI: 10.1007/s00428-017-2174-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  79 in total

1.  Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances.

Authors:  S Solinas-Toldo; S Lampel; S Stilgenbauer; J Nickolenko; A Benner; H Döhner; T Cremer; P Lichter
Journal:  Genes Chromosomes Cancer       Date:  1997-12       Impact factor: 5.006

2.  Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.

Authors:  George Jour; John D Scarborough; Robin L Jones; Elizabeth Loggers; Seth M Pollack; Colin C Pritchard; Benjamin L Hoch
Journal:  Hum Pathol       Date:  2014-04-24       Impact factor: 3.466

3.  Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.

Authors:  A Kollár; R L Jones; S Stacchiotti; H Gelderblom; M Guida; G Grignani; N Steeghs; A Safwat; D Katz; F Duffaud; S Sleijfer; W T van der Graaf; N Touati; S Litière; S Marreaud; A Gronchi; B Kasper
Journal:  Acta Oncol       Date:  2016-11-14       Impact factor: 4.089

4.  Molecular characterisation of soft tissue tumours: a gene expression study.

Authors:  Torsten O Nielsen; Rob B West; Sabine C Linn; Orly Alter; Margaret A Knowling; John X O'Connell; Shirley Zhu; Mike Fero; Gavin Sherlock; Jonathan R Pollack; Patrick O Brown; David Botstein; Matt van de Rijn
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

5.  Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas.

Authors:  Pauline Lagarde; Joanna Przybyl; Céline Brulard; Gaëlle Pérot; Gaelle Pierron; Olivier Delattre; Raf Sciot; Agnieszka Wozniak; Patrick Schöffski; Philippe Terrier; Agnès Neuville; Jean-Michel Coindre; Antoine Italiano; Daniel Orbach; Maria Debiec-Rychter; Frédéric Chibon
Journal:  J Clin Oncol       Date:  2013-01-14       Impact factor: 44.544

6.  Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Authors:  Robert G Maki; David R D'Adamo; Mary L Keohan; Michael Saulle; Scott M Schuetze; Samir D Undevia; Michael B Livingston; Matthew M Cooney; Martee L Hensley; Monica M Mita; Chris H Takimoto; Andrew S Kraft; Anthony D Elias; Bruce Brockstein; Nathalie E Blachère; Mark A Edgar; Lawrence H Schwartz; Li-Xuan Qin; Cristina R Antonescu; Gary K Schwartz
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

Authors:  Arjen H G Cleven; Ghadah A Al Sannaa; Inge Briaire-de Bruijn; Davis R Ingram; Matt van de Rijn; Brian P Rubin; Maurits W de Vries; Kelsey L Watson; Keila E Torres; Wei-Lien Wang; Sjoerd G van Duinen; Pancras C W Hogendoorn; Alexander J Lazar; Judith V M G Bovée
Journal:  Mod Pathol       Date:  2016-03-18       Impact factor: 7.842

Review 8.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.

Authors:  Jingxiang Huang; Brendan D Manning
Journal:  Biochem J       Date:  2008-06-01       Impact factor: 3.857

9.  KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.

Authors:  Cristina R Antonescu; Akihiko Yoshida; Tianhuo Guo; Ning-En Chang; Lei Zhang; Narasimhan P Agaram; Li-Xuan Qin; Murray F Brennan; Samuel Singer; Robert G Maki
Journal:  Cancer Res       Date:  2009-09-01       Impact factor: 12.701

10.  Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis.

Authors:  Daniela Egas-Bejar; Pete M Anderson; Rishi Agarwal; Fernando Corrales-Medina; Eswaran Devarajan; Winston W Huh; Robert E Brown; Vivek Subbiah
Journal:  Oncoscience       Date:  2014-03-12
View more
  1 in total

Review 1.  Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?

Authors:  Vasiliki Siozopoulou; Andreas Domen; Karen Zwaenepoel; Annelies Van Beeck; Evelien Smits; Patrick Pauwels; Elly Marcq
Journal:  Cancers (Basel)       Date:  2021-01-19       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.